1. In June 2015 your hospital was selected to take part in NHS England’s new Commissioning through Evaluation (CtE) programme to assess the value of treating certain cancer patients with Stereotactic Ablative Radiotherapy (SABR).
1a How many patients have you treated with SABR under this programme since it began? 27 patients
1b. Which indications have you treated? Lung, spine, bone (rib) and lymph node.
1c. How many patients do you plan to treat in the next twelve months? 40
2. Outside of the SABR CtE programme:-
2a How many patients have you treated with SABR since June 2015? 68 (1/6/15 – 26/8/16)
2b Which indications have you treated? Primary lung cancer.
2c How many patients do you plan to treat in the next twelve months? 50
2d Are you planning to purchase any new radiotherapy machines in the next twelve months, if so what kind of machine are you planning to purchase? Yes. Varian Linear accelerator for general radiotherapy.
3. Does your hospital deliver Stereotactic Radiosurgery (SRS) for benign or malignant tumours of the brain? As of April 1st 2016 the Trust was unable to treat NHS patients requiring SRS as the Trust was not commissioned to continue to provide this service.
3a. How many patients have you treated since April 2015? We have treated 11 SRS patients since our SRS service was first opened in November 2015.
3b. Which indications have you treated? All of the above have been treated for brain metastases.
3c. How many patients do you plan to treat in the current financial year? None, due to commissioning restriction (see response to 3 above)